Compare ELVR & AMPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ELVR | AMPH |
|---|---|---|
| Founded | 2000 | 1996 |
| Country | Australia | United States |
| Employees | 230 | N/A |
| Industry | Mining & Quarrying of Nonmetallic Minerals (No Fuels) | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 941.8M | 971.8M |
| IPO Year | N/A | 2005 |
| Metric | ELVR | AMPH |
|---|---|---|
| Price | $81.55 | $17.16 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $28.38 |
| AVG Volume (30 Days) | 84.2K | ★ 568.2K |
| Earning Date | 04-23-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.14 |
| Revenue | N/A | ★ $719,887,000.00 |
| Revenue This Year | $90.73 | $6.90 |
| Revenue Next Year | $42.59 | $4.64 |
| P/E Ratio | ★ N/A | $120.25 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $15.55 | $16.76 |
| 52 Week High | $101.50 | $31.26 |
| Indicator | ELVR | AMPH |
|---|---|---|
| Relative Strength Index (RSI) | 49.54 | 33.88 |
| Support Level | $49.59 | $17.03 |
| Resistance Level | N/A | $24.16 |
| Average True Range (ATR) | 4.01 | 0.86 |
| MACD | -2.72 | -0.60 |
| Stochastic Oscillator | 18.75 | 7.21 |
Elevra Lithium Ltd is a mineral exploration and development company. The principal activity of the company is the identification, acquisition, and evaluation of mineral exploration assets, focusing on lithium. The projects of the company include the Moblan Lithium Project, the Carolina Lithium Project, the Ewoyaa Lithium Project, North American Lithium, and other projects. The company also holds an interest in a tenement portfolio in the Pilbara region, prospective for gold and lithium.
Amphastar Pharmaceuticals Inc is a bio-pharmaceutical company focusing on developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products, as well as insulin active pharmaceutical ingredient (or insulin API products. The company's finished products are used in hospital or urgent care clinical settings and are contracted and distributed through group purchasing organizations and drug wholesalers. The company has one reportable segment: pharmaceutical products. Geographically, the business presence of the firm is seen in the United States, China, and France, of which the U.S. accounts for the majority of the revenue.